Metformin vs Insulin in the Management of Gestational Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nowadays, there have been increasing studies comparing metformin with insulin. But the use of metformin in pregnant women is still controversial, therefore, we aim to examine the efficiency and safety of metformin by conducting a meta-analysis of randomized controlled trials (RCTs) comparing the effects of metformin with insulin on glycemic control, maternal and neonatal outcomes in gestational diabetes mellitus (GDM). METHODS: We used the key words "gestational diabetes" in combination with "metformin" and searched the databases including Pubmed, the Cochrane Library, Web of knowledge, and Clinical Trial Registries. A random-effects model was used to compute the summary risk estimates. RESULTS: Meta-analysis of 5 RCTs involving 1270 participants detected that average weight gains after enrollment were much lower in the metformin group (n = 1006, P = 0.003, SMD = -0.47, 95%CI [-0.77 to -0.16]); average gestational ages at delivery were significantly lower in the metformin group (n = 1270, P = 0.02, SMD = -0.14, 95%CI [-0.25 to -0.03]); incidence of preterm birth was significantly more in metformin group (n = 1110, P = 0.01, OR = 1.74, 95%CI [1.13 to 2.68]); the incidence of pregnancy induced hypertension was significantly less in the metformin group (n = 1110, P = 0.02, OR = 0.52, 95%CI [0.30 to 0.90]). The fasting blood sugar levels of OGTT were significantly lower in the metformin only group than in the supplemental insulin group (n = 478, P = 0.0006, SMD = -0.83, 95%CI [-1.31 to -0.36]). CONCLUSIONS: Metformin is comparable with insulin in glycemic control and neonatal outcomes. It might be more suitable for women with mild GDM. This meta-analysis also provides some significant benefits and risks of the use of metformin in GDM and help to inform further development of management guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The finding that metformin decreased the frequency of preeclampsia was consistent with the findings reported in a meta-analysis by Gui et al.(75) and Feng and Yang(76).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gui et al.(75) published a systematic review and meta-analysis in which metformin was shown to be superior to insulin in reducing maternal weight gain during pregnancy as well as in the frequency of gestational hypertension (Figure 5a,); however, metformin did not change the frequency of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) fetuses or of hypoglycemia and preeclampsia(”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
In the citing paper
“Gui et al.(75) published a systematic review and meta-analysis in which metformin was shown to be superior to insulin in reducing maternal weight gain during pregnancy as well as in the frequency of gestational hypertension (Figure 5a,); however, metformin did not change the frequency of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) fetuses or of hypoglycemia and preeclampsia(”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
In the citing paper
“however, metformin did not change the frequency of large-for-gestational-age (LGA) or small-for-gestational-age (SGA) fetuses or of hypoglycemia and preeclampsia(75).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [75]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390 · cited 1×
“Furthermore, the influence of the intrauterine hyperglycemia environment might go with the children in later life [3], [9].”
BackgroundEffect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Metzger, B. E., Gabbe, S. G., Persson, B., Lowe, L. P., Dyer, A. R., Oats, J. J. N., & Buchanan, T. A. (2010) · Diabetes Care · doi:10.2337/dc10-0719 · Cited by 1,888
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720 · cited 1×
“The possible explanation might be that metformin has complex properties on endothelial functions and reactive oxygen species production [34], so as to reduce the endothelial activation and maternal inflammatory response of insulin resistance.”
BackgroundMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 5×
“In this meta-analysis, the incidence of requiring additional insulin to achieve euglycemia was especially high in the study of Rowan [27] (46.”
BackgroundMethodResultInfluentialKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“Metformin reduces hyperglycemia by suppressing hepatic glucose output (hepatic gluconeogenesis), increasing insulin sensitivity and enhancing peripheral glucose uptake [30].”
Background
Cited by
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s013 · Cited by 332
“port the efficacy and short-term safety of metformin (30,31) and glyburide (32) for the treatment of GDM, both agents”
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282
“Recently, metformin has been proposed as an adjuvant treatment for cancer [7], as a treatment for gestational diabetes and for the prevention of T2DM in pre-diabetic individuals [8].”
Background14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s014 · Cited by 265
“While individual RCTs support limited efficacy of metformin (41,42) and glyburide (43) in reducing glucose levels for the treatment of GDM, these agents are not recommended as firstline treatment for GDM because they are known to cross the placenta and data on safety for offspring is lacking (22).”
BackgroundRomero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Farahvar, S., Walfisch, A., & Sheiner, E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1476135 · Cited by 237
“it did not change the frequency of hypoglycemia, preeclampsia, or either large- or small-for-gestational-age fetuses [136].”
Background15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s015 · Cited by 232
13. Management of Diabetes in Pregnancy
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s016 · Cited by 179
“While individual randomized controlled trials support the efficacy and short-term safety of metformin (26,27) and glyburide (28) for the treatment of GDM, both agents cross the placenta.”
Butalia, S., Gutierrez, L., Lodha, A., Aitken, E., Zakariasen, A., & Donovan, L. (2017) · Diabetic Medicine · doi:10.1111/dme.13150 · Cited by 170
Treatments for gestational diabetes: A systematic review and meta-analysis
Farrar, D., Simmonds, M., Bryant, M., Sheldon, T. A., Tuffnell, D., Golder, S., & Lawlor, D. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015557 · Cited by 163
Cassina, M., Donà, M., Di Gianantonio, E., Litta, P., & Clementi, M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu022 · Cited by 143
“The available data suggest thatmetformin is as effectiveas insulin in controlling gestational diabetes and preventing complications, especially in case of mild gestational diabetes (Moore et al., 2007; Tertti et al., 2008, 2013; Balani et al., 2009; Dhulkotia et al., 2010; Goh et al., 2011; Ijas et al., 2011; Gandhi e…”
BackgroundInfluentialGuo, L., Ma, J., Tang, J., Hu, D., Zhang, W., & Zhao, X. Q. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9804708 · Cited by 157
“Two review authors independently assessed the risk of bias for each included study by using the Cochrane Collaboration’s risk-of-bias tool in the Cochrane Handbook for Systematic Reviews of Interventions [73].”
BackgroundMethodTaylor, B., Woodfall, G., Sheedy, K., O’Riley, M., Rainbow, K., Bramwell, E., & Kellow, N. (2017) · Nutrients · doi:10.3390/nu9050461 · Cited by 126
“Both insulin and metformin are considered safe for use in pregnancy, but can be associated with unwanted side effects such as gastrointestinal disturbances and hypoglycemia [52,53].”
BackgroundJiang, Y.-F., Chen, X.-Y., Ding, T., Wang, X.-F., Zhu, Z.-N., & Su, S.-W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4403 · Cited by 124
12. Management of Diabetes in Pregnancy
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s015 · Cited by 152
“Randomized controlled trials support the efficacy and short-term safety of glyburide (11) (pregnancy category B) and metformin (12,13) (pregnancy category B) for the treatment of GDM.”
BackgroundFarrar, D., Simmonds, M., Griffin, S., Duarte, A., Lawlor, D. A., Sculpher, M., Fairley, L., Golder, S., Tuffnell, D., Bland, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20860 · Cited by 117
“(PLOS ONE).(171) The search strategies of all five reviews included randomised controlled trials (RCTs), one review also included observational studies which were ineligible in our review and therefore these studies were not considered.”
Background15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 172
Poolsup, N., Suksomboon, N., & Amin, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109985 · Cited by 107
“[15,40], however, our results are more reliable due to its increased sample size.”
Result12. Management of Diabetes in Pregnancy
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s015 · Cited by 135
“Individual randomized controlled trials support the efficacy and short-term safety of metformin (19,20) (pregnancy category B) and glyburide (21) (pregnancy category B) for the treatment of GDM.”
Wouldes, T. A., Battin, M., Coat, S., Rush, E. C., Hague, W. M., & Rowan, J. A. (2016) · Archives of Disease in Childhood - Fetal and Neonatal Edition · doi:10.1136/archdischild-2015-309602 · Cited by 95
SMFM statement: pharmacological treatment of gestational diabetes
(2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.041 · Cited by 94
“gestational age at delivery, less gestational hypertension, and less neonatal hypoglycemia 47 (7, 15).”
BackgroundBedell, S. (2021) · Current Vascular Pharmacology · doi:10.2174/18756212mta3qndapy · Cited by 57
Kalafat, E., Sukur, Y. E., Abdi, A., Thilaganathan, B., & Khalil, A. A. (2018) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.19084 · Cited by 100
Shpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Immunoendocrine Dysregulation during Gestational Diabetes Mellitus: The Central Role of the Placenta
Olmos‐Ortiz, A., Flores‐Espinosa, P., Díaz, L., Velázquez, P., Ramírez-Isarraraz, C., & Zaga‐Clavellina, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158087 · Cited by 98
Metformin in Pregnancy: Mechanisms and Clinical Applications
Hyer, S., Balani, J., & Shehata, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071954 · Cited by 78
“insulin treated patients although these differences did not achieve statistical significance [35].”
Metformin in the management of diabetes during pregnancy and lactation
Priya, G., & Kalra, S. (2018) · Drugs in Context · doi:10.7573/dic.212523 · Cited by 99
“, 2013 [42] 5 RCTs, 1270 participants; metformin versus insulin Lower maternal weight gain (p=0.”
BackgroundMetformin versus insulin for gestational diabetes: a systematic review and meta-analysis
Bao, L.-X., Shi, W., & Han, Y. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1670804 · Cited by 82
“In contrast to previous publications [40,41], we found no increased risk of preterm delivery in women with GDM who were randomized to metformin group.”
ResultComparison of glyburide and insulin in the management of gestational diabetes: a meta-analysis
Song, R., Chen, L., Chen, Y., Si, X., Liu, Y., Liu, Y., Irwin, D. M., & Feng, W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182488 · Cited by 73
Gestational diabetes mellitus: challenges in diagnosis and management
Mpondo, B. C. T., Ernest, A. I., & Dee, H. E. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0169-7 · Cited by 85
“Meanwhile, a 2013 meta-analysis found that metformin is comparable to insulin regarding glycaemic control and neonatal outcomes [50].”
BackgroundHastie, R. M., Brownfoot, F., Pritchard, N., Hannan, N. J., Cannon, P., Nguyen, V., Palmer, K. R., Beard, S., Tong, S., & Kaitu’u‐Lino, T. J. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12300 · Cited by 88
Asemi, Z., Karamali, M., Jamilian, M., Foroozanfard, F., Bahmani, F., Heidarzadeh, Z., Benisi-Kohansal, S., Surkan, P. J., & Esmaillzadeh, A. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.098616 · Cited by 82
“In addition to strategies focused on diet (8, 9), vitamin supplementation (10–12), and pharmaceutical interventions (13), some studies have shown a significant inverse relation between dietary magnesium intake and glucose homeostasis in patients with GDM (2, 14).”
BackgroundRetractedFeng, Y., & Yang, H. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1228061 · Cited by 68
“The reason might be that it takes time for the participants to master the usage and dose computation of insulin [32].”
BackgroundWoldeamlak, B., Yirdaw, K., & Biadgo, B. (2019) · The Korean Journal of Gastroenterology · doi:10.4166/kjg.2019.74.6.314 · Cited by 66
“Recently, metformin has been proposed as an adjuvant treatment for cancer,(68) as a treatment for gestational diabetes, and for the prevention of T2DM in pre-diabetic individuals.(69) Stades et al.”
BackgroundEllerbrock, J., Spaanderman, B., van Drongelen, J., Mulder, E., van Balen, V. A. L., Schiffer, V. M. M. M., Jorissen, L. M., Alers, R., Leenen, J., Ghossein‐Doha, C., et al. (2022) · Nutrients · doi:10.3390/nu14122444 · Cited by 75
Metformin versus insulin for gestational diabetes mellitus: a meta-analysis
Zhao, L., Sheng, X., Zhou, S., Yang, T., Ma, L., Zhou, Y., & Cui, Y. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12672 · Cited by 63
“The incidence of preterm birth, perinatal death, RDS, and phototherapy did not differ between the two groups, and the result of preterm birth refreshed the previous review [13].”
BackgroundResultInfluentialOwens, L. A., Egan, A. M., Carmody, L., & Dunne, F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3817 · Cited by 63
“001 1st trimester 7% 44 (37) 110 (59) .”
BackgroundUse of oral anti-diabetic agents in pregnancy: A pragmatic approach
Kalra, S., Gupta, Y., Kalra, B., & Singla, R. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.150081 · Cited by 61
“North American Journal of Medical Sciences | Jan 2015 | Volume 7 | Issue 1 | 8 signifi cant difference in the pre-eclampsia rate between the two groups.[9] Average gestational ages at delivery was signifi cantly lower in the metformin group.”
BackgroundResultInfluentialScreening and management of gestational diabetes
Benhalima, K., Devlieger, R., & Assche, A. V. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.07.026 · Cited by 78
“Studies of the use of metformin in GDM show equivalent pregnancy outcomes, while reporting reduction in weight gain and less maternal hypoglycemia [69].”
BackgroundAntidiabetic medication use during pregnancy: an international utilization study
Cesta, C. E., Cohen, J. M., Pazzagli, L., Bateman, B. T., Bröms, G., Einarsdóttir, K., Furu, K., Havard, A., Heino, A., Hernández–Díaz, S., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000759 · Cited by 65
Metformin for the treatment of gestational diabetes: An updated meta-analysis
Kitwitee, P., Limwattananon, S., Limwattananon, C., Waleekachonlert, O., Ratanachotpanich, T., Phimphilai, M., Nguyen, T. V., & Pongchaiyakul, C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.017 · Cited by 55
“Our results confirmed the findings from previous meta-analyses [16,18] which reported a similar efficacy on the glycemic control between OHAs (metformin and glyburide) and insulin [15].”
BackgroundMethodResultInfluentialBenhalima, K., Robyns, K., Van Crombrugge, P., Deprez, N., Seynhave, B., Devlieger, R., Verhaeghe, J., Mathieu, C., & Nobels, F. (2015) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-015-0706-x · Cited by 55
“Some studies have suggested that metformin may be a safe and acceptable alternative for the treatment of GDM with less maternal weight gain compared to insulin and with no increase in congenital anomalies, despite it crossing the placenta [8, 26, 27].”
BackgroundLiang, H.-L., Ma, S.-J., Xiao, Y.-N., & Tan, H.-Z. (2017) · Medicine · doi:10.1097/md.0000000000007939 · Cited by 57
Li, G., Zhao, S., Cui, S., Li, L., Xu, Y., & Li, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3566-0 · Cited by 54
“This finding is consistent with the previous meta-analysis [26], and suggests a few benefits and risks of”
BackgroundResultGestational Diabetes Mellitus:current knowledge and unmet needs
Koning, S. H., Hoogenberg, K., Lutgers, H. L., van den Berg, P. P., & Wolffenbuttel, B. H. R. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12422 · Cited by 61
“Conversely, compared with insulin therapy, metformin was associated with less maternal weight gain and lower rates of pregnancyinduced hypertension, the latter thought to be explained by insulin-mediated sodium retention.76 Recently, five other meta-analyses have been published comparing metformin and insulin therapy…”
BackgroundMethodResultInfluentialBeyuo, T., Obed, S. A., Adjepong-Yamoah, K. K., Bugyei, K. A., Oppong, S. A., & Marfoh, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125712 · Cited by 48
“Metformin has been shown not to be inferior to insulin for glycemic control in GDM [7, 8, 9].”
BackgroundKaitu’u‐Lino, T. J., Brownfoot, F., Beard, S., Cannon, P., Hastie, R. M., Nguyen, T. V., Binder, N. K., Tong, S., & Hannan, N. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0188845 · Cited by 50
Efficacy and safety of metformin during pregnancy: an update
Paschou, S. Α., Shalit, A., Gerontiti, E., Athanasiadou, K. I., Kalampokas, T., Ψαλτοπούλου, Θ., Lambrinoudaki, I. V., Anastasiou, E., Wolffenbuttel, B. H. R., & Goulis, D. G. (2023) · Endocrine · doi:10.1007/s12020-023-03550-0 · Cited by 60
“The collective verdict from multiple RCTs and meta-analyses is that metformin administration during pregnancy is not associated with NICU admissions, respiratory distress syndrome, or reduced APGAR score at 5 min [9, 10, 17, 20, 22, 26, 29, 31, 38, 43, 47].”
BackgroundResultInfluentialCluver, C. A., Walker, S. P., Mol, B. W., Hall, D. R., Hiscock, R. J., Brownfoot, F., Kaitu’u‐Lino, T. J., & Tong, S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025809 · Cited by 49
“In strong support of our preclinical data are meta-analyses of clinical trial data that have shown a decrease in the incidence of hypertensive disorders when metformin has been used for other indications.(29) Excitingly, a randomised trial by the Fetal Medicine Foundation (for obese women without diabetes) reported th…”
ResultKrstevska, S. S., Bogoev, M. K., Bogoeva, K., Zisovska, E., Samardziski, I., Nakova, V. V., Livrinova, V., Todorovska, I., Sima, A., & Blazevska-Siljanoska, V. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.200 · Cited by 49
“Contrary there is a number of studies with opposite findings10, [13] [14] [15] [16] [17].”
ResultMukona, D., Munjanja, S. P., Zvinavashe, M., & Stray-Pederson, B. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3578075 · Cited by 45
“Metformin is not yet recommended as an oral alternative for insulin despite its proven comparability [36], but its ease of use, and reduced risk of hypoglycaemia, less strict glucose monitoring, lower cost, and having no particular storage and refrigeration requirements makes it a better and safer alternative for deve…”
BackgroundMetformin during Pregnancy: Effects on Offspring Development and Metabolic Function
Jorquera, G., Echiburú, B., Crisosto, N., Sotomayor‐Zárate, R., Maliqueo, M. A., & Cruz, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00653 · Cited by 49
The emerging role of metformin in gestational diabetes mellitus
Gray, S. G., McGuire, T. M., Cohen, N., & Little, P. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12893 · Cited by 40
Semnani‐Azad, Z., Gaillard, R., Hughes, A. E., Boyle, K. E., Tobias, D. K., PMDI, A., Tobias, D. K., Merino, J., Ahmad, A., Aiken, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-023-00427-1 · Cited by 43
Abolhassani, N., Winterfeld, U., Kaplan, Y. C., Jaques, C., Minder, B., Giovane, C. D., & Panchaud, A. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002919 · Cited by 43
Africa, C. W. J., & Turton, M. (2019) · International Journal of Dentistry · doi:10.1155/2019/5475973 · Cited by 53
“e study included patients with confirmed pregnancy aged 18 years and older and excluded mothers with chronic conditions such as diabetes mellitus [18], congenital heart disease [19], pulmonary hypertension [20], and asthma [21] and those on substance use including alcohol and illicit drugs such as cannabis, cocaine, a…”
BackgroundHashim, H. A., Foda, O., & Ghayaty, E. (2015) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12673 · Cited by 42
“The safety of metformin during the first trimester of pregnancy and beyond has also been shown (46,47).”
BackgroundAmin, M., Suksomboon, N., Poolsup, N., & Malik, O. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0289-3 · Cited by 40
“receiving metformin were switched to insulin therapy during the course of the study [39].”
MethodResultGestational diabetes mellitus: Prevention, diagnosis and treatment. A fresh look to a busy corner
Zito, G., Corte, L. D., Giampaolino, P., Terzić, M., Terzic, S., Guardo, F. D., Ricci, G., Pietà, I. D., Maso, G., & Garzon, S. (2019) · Journal of Neonatal-Perinatal Medicine · doi:10.3233/npm-190305 · Cited by 43
“It is not clear if it can be associated to increased rate of pre term birth compared to insulin [68, 101].”
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
“105,106 Consistently, in a clinical trial on pregnant women with type 2 diabetes on insulin therapy, adding metformin to insulin was associated with a reduction in maternal weight gain and a lower risk of large-for-gestational-age newborn and caesarean births, in respect to insulin alone; on the…”
Bashir, M., Aboulfotouh, M. E., Dabbous, Z., Mokhtar, M. G., Siddique, M. A., Wahba, R. M., Ibrahim, A., Brich, S., Konje, J. C., & Abou‐Samra, A. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1550480 · Cited by 38
“Metformin was shown to reduce gestational weight gain, hypertensive disorders during pregnancy, macrosomia, neonatal hypoglycemia, and intensive care unit admissions [12,13].”
BackgroundPharmacological Management of Gestational Diabetes Mellitus
Mukerji, G., & Feig, D. S. (2017) · Drugs · doi:10.1007/s40265-017-0807-0 · Cited by 40
“Other meta-analyses have noted similar findings of lower weight gain [55, 56], shorter gestational age [55, 56], and less pregnancy-induced hypertension [55, 56] with metformin compared to insulin; however, the data on preterm birth with metformin use has been conflicting, with some meta-analyses showing an increased…”
ResultConsensus evidence-based guidelines for management of gestational diabetes mellitus in India.
Seshiah, V., Banerjee, S., Balaji, V., Muruganathan, A., & Das, A. K. (2014) · PubMed · Cited by 30
Tosti, G., Barberio, A., Tartaglione, L., Rizzi, A., Leo, M. A. S. D., Viti, L., Sirico, A., Carolis, S. D., Pontecorvi, A., Lanzone, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1176623 · Cited by 36
“Picón-César 2021 (24) 200 14–35 425–2,550 Insulin < / < = = = = =”
BackgroundInfluentialZhu, B., Zhang, L., Fan, Y., Wang, L., Li, X., Liu, T., Cao, Y., & Zhao, Z. (2016) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-016-1414-x · Cited by 28
“who had just showed that metformin was more suitable for women with mild GDM [21].”
Öztürk, F. Y., & Altuntaş, Y. (2015) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.5350/semb.20150317014238 · Cited by 36
Management of Polycystic Ovary Syndrome in India
Malik, S., Jain, K., Talwar, P., Prasad, S., Dhorepatil, B., Devi, G., Khurana, A., Bhatia, V., Chandiok, N., Kriplani, A., et al. (2014) · Fertility Science and Research · doi:10.4103/2394-4285.146798 · Cited by 43
“A latest meta-analysis of RCTs (n=5) comparing the effects of metformin with insulin on glycaemic control, maternal and neonatal outcomes in GDM concluded that metformin is comparable with insulin and might be more suitable for women with mild GDM.[149] An observational study from India reported significantly higher b…”
BackgroundRojas, J., Chávez-Castillo, M., & Bermúdez, V. (2014) · International Journal of Reproductive Medicine · doi:10.1155/2014/797681 · Cited by 27
“Insulin remains the most recommended option in mild cases of GDM [170] and in women with elevated BMI [171].”
BackgroundSina, M., Cade, T. J., Flack, J., Nolan, C. J., Rajagopal, R., Wong, V., Burcher, L., Barry, A., Gianatti, E., McCarthy, A., et al. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13144 · Cited by 27
Metformin in gestational diabetes: An emerging contender
Singh, A. K., & Singh, R. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.149317 · Cited by 31
“[29,30] However, these meta‑analysis hinted at significantly higher preterm birth in the metformin arm, compared to insulin [Table 3].”
Pellonperä, O., Rönnemaa, T., Ekblad, U., Vahlberg, T. J., & Tertti, K. (2015) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12788 · Cited by 27
“Metformin is known to reduce the weight gain of women with GDM during pregnancy (13,14).”
BackgroundVenkatesh, K. K., Chiang, C., Castillo, W. C., Battarbee, A., Donneyong, M. M., Harper, L. M., Costantine, M. M., Saade, G. A., Werner, E., Boggess, K., et al. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16960 · Cited by 29
Cao, Q., Hu, Y., Fu, J., Huang, X., Wu, L., Zhang, J., & Huang, W. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15044 · Cited by 26
“In two earlier meta-analyses and a recent RCT study, metformin increased preterm delivery versus insulin in women with GDM.(23,32,33) However, since these studies were performed in women with GDM, it is of limited significance to us, especially when animal experiments and mechanism studies have initially confirmed the…”
ResultInfluentialDiabetes: how to manage gestational diabetes mellitus
Mukherjee, S. M., & Dawson, A. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-12 · Cited by 33
Utz, B., Kolsteren, P. W., & Brouwere, V. D. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.3.152 · Cited by 24
Pharmacological treatment of gestational diabetes mellitus: point/counterpoint
Langer, O. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.024 · Cited by 27
Association of diabetes and microbiota: An update
Al-Jameel, S. S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.04.041 · Cited by 25
“Not only this, but metformin has also been proposed as a treatment of gestational diabetes and T2D prevention in prediabetic individuals (Wu et al., 2017; Gui et al., 2013).”
BackgroundEid, S. R., Moustafa, R. S. I., Salah, M. M., Hanafy, S. K., Aly, R. H., Mostafa, W. G., & Ghanem, A. I. M. (2018) · Egyptian Pediatric Association Gazette · doi:10.1016/j.epag.2018.01.002 · Cited by 24
Prevention of Hypertensive Disorders of Pregnancy—Is There a Place for Metformin?
Poniedziałek‐Czajkowska, E., Mierzyński, R., Dłuski, D. F., & Leszczyńska‐Gorzelak, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132805 · Cited by 22
Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy
Polasek, T. M., Doogue, M. P., & Thynne, T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618769831 · Cited by 21
Pharmacotherapy for gestational diabetes
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509955 · Cited by 19
“gain, shorter gestational age, and less pregnancy-induced hypertension with metformin compared to insulin [70,71].”
BackgroundIs it worth treating gestational diabetes: if so, when and how?
Vääräsmäki, M. (2016) · Diabetologia · doi:10.1007/s00125-016-3976-6 · Cited by 22
“Treatment failures are associated with severe cases of GDM defined by early GDM diagnosis and need for medication, maternal obesity, high fasting glucose numbers and prior GDM [43, 44].”
Backgrounddo Nascimento, I. B., Dienstmann, G., de Souza, M. L. R., Fleig, R., Hoffmann, C. B. P. C., & Silva, J. C. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1675214 · Cited by 21
Huang, L., Yue, P., Wu, X., Yu, T., Wang, Y., Zhou, J., Kong, D., & Chen, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195609 · Cited by 21
Metformin Safety in the Management of Gestational Diabetes
Marques, P., Carvalho, M. R., Luísa, & Guerra, S. (2014) · Endocrine Practice · doi:10.4158/ep14018.or · Cited by 22
Vanlalhruaii, Dasgupta, R., Ramachandran, R., Mathews, J. E., Regi, A., Thomas, N., Gupta, V., Visalakshi, P., Asha, H. S., Paul, T. V., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.002 · Cited by 17
Vounzoulaki, E., & Seidu, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_35 · Cited by 17
Zhang, Y., Liu, X., Yang, L., & Zou, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.596145 · Cited by 16
“Likewise, average weight gains after enrollment were much lower in the MET group (Gui et al., 2013).”
BackgroundBolte, E., Dean, T. A., Garcia, B. T., Seferovic, M. D., Sauter, K. A. D., Hummel, G. L., Bucher, M., Li, F., Hicks, J. M., Qin, X., et al. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.06.002 · Cited by 21
Metformin in gestational diabetes: physiological actions and clinical applications
Mason, T., Alesi, S., Fernando, M., Vanky, E., Teede, H. J., & Mousa, A. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01049-w · Cited by 20
“…from individual RCTs, potential benefits of metformin include lower rates of neo natal hypoglycaemia 136,139,145–152 , emergency Caesarean section 136,140 , hypertensive disorders in pregnancy 137,139,143,147,151–154 and NICU admissions 137,151,152,155,156 as well as less gestational weight gain…”
Gui, J., Li, A., Su, X., & Feng, L. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-34 · Cited by 17
“exercise, oral hypoglycemic agents and insulin therapy could reduce the risk of complications and improve maternal and neonatal outcomes [18-22].”
BackgroundSelf-citationGray, S. G., Sweeting, A., McGuire, T., Cohen, N. D., Ross, G. P., & Little, P. J. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12660 · Cited by 17
Longer-term outcomes in offspring of GDM mothers treated with metformin versus insulin
Zhen, X. M., Li, X., & Chen, C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.002 · Cited by 17
Mousa, A., Løvvik, T. S., Nikkinen, H., Carlsen, S. M., Morin-Papunen, L. C., Tertti, K., Rönnemaa, T., Syngelaki, A., Nicolaides, K. H., Shehata, H. A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-036981 · Cited by 17
Metadata
- Authors
- Gui, J., Liu, Q., & Feng, L.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Feng, Ling
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-27
- Volume
- 8
- Issue
- 5
- Pages
- e64585
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3664585
- OpenAlex
- W2109810300
- Cited by
- 222
- References
- 37
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 22 · 2020: 15 · 2019: 19 · 2018: 31 · 2017: 13 · 2016: 12 · 2015: 34 · 2014: 19 · 2013: 3
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, glycemic control, maternal outcomes, neonatal outcomes, preterm birth, gestational hypertension, gestational weight gain, fasting blood glucose, oral glucose tolerance test
- MeSH terms
- Birth Weight, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Metformin, Pregnancy, Pregnancy Outcome, Diabetes, Gestational, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.